http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-PI0510044-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8eb0e5ee0f2f935c2e8acb6607c0b3ea |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2031 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-209 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-08 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K- http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-24 |
| filingDate | 2005-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e3057bd01fd5f4a48ffd80cf3dc56e2a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cc07ff610460001597996346cb072a48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_52a935ff823dab27a24cbea657234121 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f35d95f2b6849081b1bdebd5cf3a012d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8af0741b712122a1467e1abb2ae75121 |
| publicationDate | 2019-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-PI0510044-B1 |
| titleOfInvention | pharmaceutical composition and use of a pharmaceutical composition |
| abstract | pharmaceutical composition, kit, method for treating an individual, and use of a first and a second amount of one or more glucocorticoids. The invention relates to glucocorticoid replacement therapy and provides pharmaceutical compositions and kits designed to supply one or more glucocorticoids to an individual in need thereof, in a manner that results in glucocorticoid serum levels that essentially mimic those of a healthy individual. for a clinically relevant period of time. the pharmaceutical composition comprises one or more glucocorticoids, wherein a first part of one or more glucocorticoids is substantially and immediately released over an extended period of time of at least about 8 hours, and the amount of one or more glucocorticoids of the first part, expressed as hydrocortisone equivalents, is in the range of about 15 to about 50% of the total hydrocortisone equivalents. The invention also relates to a method of treating diseases requiring glucocorticoid treatment, such as in individuals having a glucocorticoid deficiency disorder. in another aspect, the invention relates to the use of a first and a second amount of one or more glucocorticoids for the preparation of a pharmaceutical composition or kit for treating a glucocorticoid deficiency disorder. |
| priorityDate | 2004-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 134.